Table 1 Clinicopathological characteristics and subtype distribution of the combined cohort evaluated in this study
GSE41998 [21] | % | GSE25066 [19] | % | GSE32646 [20] | % | GSE22226 [22] | % | TOTAL | % | |
|---|---|---|---|---|---|---|---|---|---|---|
N | 279 | – | 508 | – | 115 | – | 55 | – | 957 | – |
Age, years (mean) | 49 | – | 50 | – | 51 | – | 49 | – | 50 | – |
Tumor size | ||||||||||
T0-T2 | 177 | 64.1 % | 288 | 56.7 % | 92 | 80 % | 27 | 50.0 % | 584 | 61.3 % |
T3-T4 | 99 | 35.9 % | 220 | 43.3 % | 23 | 20 % | 27 | 50.0 % | 369 | 38.7 % |
ER IHC status | ||||||||||
Positive | 108 | 38.7 % | 297 | 59.2 % | 71 | 62 % | 31 | 58.5 % | 507 | 53.4 % |
Negative | 171 | 61.3 % | 205 | 40.8 % | 44 | 38 % | 22 | 41.5 % | 442 | 46.6 % |
PR IHC status | ||||||||||
Positive | 99 | 35.6 % | 243 | 48.5 % | 45 | 39 % | 21 | 39.6 % | 408 | 43.1 % |
Negative | 179 | 64.4 % | 258 | 51.5 % | 70 | 61 % | 32 | 60.4 % | 539 | 56.9 % |
Triple-negative status | ||||||||||
No | 139 | 49.8 % | 330 | 65.0 % | 89 | 77 % | 47 | 88.7 % | 605 | 63.4 % |
Yes | 140 | 50.2 % | 178 | 35.0 % | 26 | 23 % | 6 | 11.3 % | 350 | 36.6 % |
HER2 IHC/FISH status | ||||||||||
Negative | 251 | 90.0 % | 485 | 98.8 % | 81 | 70 % | 24 | 49.0 % | 841 | 90.0 % |
Positive | 28 | 10.0 % | 6 | 1.2 % | 34 | 30 % | 25 | 51.0 % | 93 | 10.0 % |
Histological grade | ||||||||||
1 | – | – | 32 | 6.8 % | 16 | 13.9 % | 2 | 3.6 % | 50 | 14.9 % |
2 | – | – | 180 | 38.2 % | 78 | 67.8 % | 27 | 49.1 % | 285 | 48.2 % |
3 | – | – | 259 | 55.0 % | 21 | 18.3 % | 26 | 47.3 % | 306 | 51.8 % |
Nodal status | ||||||||||
N0 | – | – | 157 | 31 % | 32 | 28 % | – | – | 189 | 30.3 % |
N1-3 | – | – | 351 | 69 % | 83 | 72 % | – | – | 434 | 69.7 % |
pCR rate | ||||||||||
No | 184 | 72.7 % | 389 | 79.7 % | 88 | 77 % | 37 | 68.5 % | 698 | 76.7 % |
Yes | 69 | 27.3 % | 99 | 20.3 % | 27 | 23 % | 17 | 31.5 % | 212 | 23.3 % |
PAM50 | ||||||||||
Luminal A | 91 | 32.6 % | 155 | 30.5 % | 30 | 26 % | 17 | 30.9 % | 293 | 30.6 % |
Luminal B | 33 | 11.8 % | 109 | 21.5 % | 23 | 20 % | 9 | 16.4 % | 174 | 18.2 % |
HER2-E | 23 | 8.2 % | 40 | 7.9 % | 24 | 21 % | 12 | 21.8 % | 99 | 10.3 % |
Basal-like | 110 | 39.4 % | 171 | 33.7 % | 21 | 18 % | 11 | 20.0 % | 313 | 32.7 % |
Normal-like | 22 | 7.9 % | 33 | 6.5 % | 17 | 15 % | 6 | 10.9 % | 78 | 8.2 % |